Azithromycin in the Successful Management of COVID-19: A Family Physician’s Perspective
Family/General Practice
[키워드] absence
acute respiratory syndrome
Ambulatory treatment
anti-inflammatory properties
antibiotic
Antiviral
antiviral activity
Antiviral effect
association
Asthma
Azithromycin
bacterial co-infection
benefit
bronchial epithelial cells
Brooklyn
Care
Clinical diagnosis
clinical study
Community
Compliance
Complication
coronavirus
Coronavirus disease-19
coughing
Course
COVID-19
COVID-19 disease
COVID-19 infection
COVID-19 outbreak
COVID-19 pandemic
COVID-19 progression
Critical care
death
Deterioration
discharge
disease course
Dyspnea
Efficacy
Epidemiology
family
FIVE
Hospitalization
Hydroxychloroquine
IMPROVE
incidence
Infection
infection with COVID-19
initial
majority
management
nasal
New York City
NIH
pandemic
Patient
patient hospitalization
patients treated
patients with COVID-19
Physicians
presenting
Prevent
primary care
pro-inflammatory
provided
pulmonary complication
pulmonary condition
Pulmonary function
Randomized controlled trial
reducing
responsible
RNA viruses
SARS-CoV-2
severity
Shortness of breath
shown
supplemental oxygen
supportive therapy
Symptom
symptom duration
Symptoms
the patient
treat
Treatment
unique
wheezing
[DOI] 10.7759/cureus.14574 PMC 바로가기 [Article Type] Family/General Practice
[DOI] 10.7759/cureus.14574 PMC 바로가기 [Article Type] Family/General Practice